<?xml version="1.0" encoding="UTF-8"?>
<p>In recent decades, the world has been shaken by the emergence and spread of new viral diseases. Although the world’s response to the 2014–2015 Ebola epidemic was laudable, there is a general consensus that much more could have been done to prevent the deaths of thousands of people and billions of dollars of economic damage as a result of this epidemic (
 <xref rid="ref1" ref-type="bibr">1</xref>). Despite many laboratory studies of candidate vaccines, before the trials of the vesicular stomatitis virus–Ebola virus vaccine (Merck, Kenilworth, New Jersey) in Guinea in 2016, no vaccine had ever been developed in time to alter the course of a new disease outbreak, and that vaccine arrived late in the epidemic (
 <xref rid="ref2" ref-type="bibr">2</xref>). Until quite recently, coordination of stakeholder responses across institutions and sectors has lagged behind the epidemic curves of emerging infectious diseases (EIDs) (
 <xref rid="ref3" ref-type="bibr">3</xref>). Research and development (R&amp;D) priorities for improving preparedness have been driven primarily by bioterrorism concerns in some countries, leaving sparse product development pipelines for EIDs that fall outside national security agendas (
 <xref rid="ref2" ref-type="bibr">2</xref>). In addition, development of EID countermeasures has been unappealing for manufacturers, who see little commercial benefit, because of the sporadic disease burden and lengthy, risky, and costly product development (
 <xref rid="ref4" ref-type="bibr">4</xref>).
</p>
